Larimar Therapeutics Inc
For the period ended Mar 31, 2025. Filed Apr 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Apr 30, 2025
LRMR$2.39+3.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| LARIMAR THERAPEUTICS, INC. | ||
| Date: April 30, 2025 | By: | /s/ Carole S. Ben-Maimon, M.D. |
|---|---|---|
| Carole S. Ben-Maimon, M.D. | ||
| President and Chief Executive Officer(Principal Executive Officer) | ||
| Date: April 30, 2025 | By: | /s/ Michael Celano |
| Michael Celano | ||
| Chief Financial Officer(Principal Financial and Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.